Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Smart inhaler study scrapped before it even started

NCT ID NCT07053696

Knowledge-focused Sponsor: Andrey Petrov Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled This study
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study was designed to test a new breath-activated inhaler (EDDIS) in healthy adults. Participants would have inhaled a tiny amount of radioactive liquid to see how well the device delivers medication to the lungs. The study was withdrawn before any volunteers were enrolled, so no results are available.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Started

Mar 2025

Finished

Nov 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

21 to 75 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age between 18 and 45 years * Healthy adults with no clinically significant medical history * Normal spirometry (FEV1 ≥ 80% predicted) * Body Mass Index (BMI) between 18.5 and 29.9 kg/m² * No prior exposure to radiopharmaceuticals in the past 12 months * Able and willing to comply with study procedures and provide written informed consent * Current or past use of tobacco products or electronic nicotine delivery systems (e.g., e-cigarettes) is not an exclusion criterion Exclusion Criteria: * History of asthma, COPD, or other chronic respiratory conditions * History of lung surgery, pulmonary embolism, or interstitial lung disease * Any ongoing respiratory infection or fever ≥ 38.0°C at screening or study day * Uncontrolled or progressive arterial hypertension * Known cardiovascular disease (e.g., arrhythmia, ischemic heart disease, heart failure) * Presence of blood in saliva, hemoptysis, or any known pulmonary bleeding * Diagnosed pulmonary emphysema * Known coagulation disorders or use of anticoagulant therapy * History of hypersensitivity to perfluorocarbons, DTPA, or radiopharmaceutical agents * Prior exposure to radiopharmaceuticals within the last 12 months * Participation in another clinical trial within the last 60 days * Pregnancy or breastfeeding * Use of any investigational or prescription drug within 30 days prior to study drug administration * Any condition which, in the opinion of the investigator, would pose a health risk or interfere with study interpretation

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Healthy volunteers are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Healthy volunteers

Contacts and locations

Locations

  • Andrey Petrov Dr

    Lausanne, Canton of Vaud, CH-1005, Switzerland

More trials for these conditions

Other studies related to the condition(s) this trial covers.